China Creates Virus In Lab That Can Kill Host Within Two To Three Days! What If American Agency DARPA Gets Hold Of It!

Medical News: In a chilling development, scientists at China's Hebei Medical University have created a virus that can kill lab hamsters within two to three days. This news has sent shockwaves through the scientific community and beyond, raising fears of a new potential global threat. The virus, engineered using parts of the Ebola virus, was ostensibly developed to study the disease and its symptoms more effectively. However, the alarming lethality of this pathogen has sparked significant concern. Amny are asking international organizations to penalize China for conducting such experiments while others are concerned if American agencies that are possibly linked to the WEF like DARPA gets hold of the virus!


China Creates Virus In Lab That Can Kill Host Within Two To Three Days
Image - AI generated
 
A Laboratory Creation
The research reveals that the scientists used a glycoprotein found in the Ebola virus to create the pathogen. This glycoprotein facilitates the virus's ability to infect cells and spread throughout the body. The genetically modified virus, a variant of vesicular stomatitis virus (VSV), caused severe systemic illnesses in lab hamsters, including multi-organ failure, similar to the symptoms observed in human Ebola patients.
 
Alarming Symptoms
The infected hamsters exhibited symptoms that mirrored those seen in humans suffering from Ebola. Some hamsters developed scabs over their eyeballs, affecting their vision, which the researchers noted could provide insights into optic nerve disorders caused by Ebola virus disease (EVD). These findings were significant enough to suggest the potential use of these infected hamsters as models for studying such optic disorders.
 
Ethical and Safety Concerns
The experiments were conducted following approval from the animal experimental committee of the Laboratory Animal Center, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science. Despite the ethical oversight, the creation of such a deadly virus in a laboratory setting has ignited a debate about the risks and benefits of this type of research.
 
The Shadow of COVID-19
This development comes against the backdrop of ongoing debates and conspiracy theories about the origins of the COVID-19 pandemic, which some claim originated from a lab in Wuhan, China that was funded by American government agencies! The creation of another potentially deadly virus in a Chinese lab adds fuel to these fears, highlighting the global implications of such research.
 
The Study’s Purpose
According to the researchers who told various Medical News outlets, the goal of their study was to replicate Ebola sympto ms in a controlled laboratory environment to better understand the disease and develop prevention strategies. By using VSV to transport the Ebola glycoprotein, the scientists avoided the need for Biosafety Level 4 (BSL-4) facilities, which are required for handling the deadly Ebola virus.
 
A Surrogate Model for Ebola
The researchers emphasized that their work provides a surrogate model for studying Ebola virus disease under BSL-2 conditions. This model could accelerate technological advances and breakthroughs in confronting Ebola virus disease by offering a safer and more economical tool for preclinical evaluation of medical countermeasures.
 
Highlights of the Study
The study's key findings include:
-Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (VSV-EBOV/GP) is lethal in immunocompetent Syrian hamsters.
 
-The pathogenicity of VSV-EBOV/GP is species-specific, age-related, gender-associated, and challenge route-dependent.
 
-Infected Syrian hamsters develop severe systemic diseases resembling human Ebola virus disease, including uveitis and multi-organ failure.
 
-The model is suitable for evaluating anti-Ebola virus antibodies and vaccines under BSL-2 conditions.
 
Understanding Ebola Virus
Ebola virus (EBOV) is part of the Orthoebolavirus genus within the Filoviridae family. It causes severe hemorrhagic fever with a high fatality rate. The largest outbreak, between 2013 and 2016, resulted in over 11,000 deaths. The virus spreads through contact with infected blood, tissues, organs, bodily fluids, and contaminated items. Symptoms include fever, headache, sore throat, rash, vomiting, diarrhea, and, in severe cases, multi-organ failure, hemorrhage, and death.
 
The Need for Animal Models
Accurate animal models are crucial for studying Ebola virus disease and developing countermeasures. Current models include mice, guinea pigs, ferrets, Syrian hamsters, and non-human primates (NHPs). However, each model has limitations, such as ethical issues, costs, and the need for high containment labs.
Therefore, more accessible and convenient animal models are urgently needed.
 
The VSV-EBOV/GP Model
In this study, the researchers constructed a recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (VSV-EBOV/GP) to serve as a surrogate for Ebola virus infection in hamsters. This model replicated several critical aspects of human Ebola virus disease, including severe systemic diseases, high viral loads, and multi-organ failure. It also provided a valuable tool for screening vaccines and antibodies under BSL-2 conditions.
 
Testing Medical Countermeasures
The study validated two medical countermeasures: equine anti-Ebola virus immunoglobulins and a subunit vaccine. The equine anti-Ebola immunoglobulins showed complete neutralizing activity against VSV-EBOV/GP and protected hamsters from lethal infection. The subunit vaccine also provided protective efficacy, reducing viral loads and alleviating pathological damage.
 
Broader Implications
The creation of the VSV-EBOV/GP model represents a significant advancement in the field of Ebola virus research. It offers a cost-effective and accessible method for evaluating medical countermeasures and understanding the disease's pathogenesis. However, it also underscores the ethical and safety concerns associated with creating and studying deadly pathogens in laboratory settings.
 
Conclusion
The study conducted by scientists at Hebei Medical University has provided a valuable surrogate model for studying Ebola virus disease. While this research holds promise for advancing our understanding and prevention of Ebola, it also raises important ethical and safety questions. The creation of such a deadly virus, even for research purposes, must be carefully managed to prevent potential global threats.
 
In a world still grappling with the fallout from the COVID-19 pandemic, the creation of another potentially deadly virus in a laboratory highlights the need for stringent oversight and international cooperation in virological research. As we strive to advance scientific knowledge and develop effective countermeasures against deadly diseases, we must also ensure that the risks are minimized and managed responsibly.
 
The study findings of the development of these viruses were published in the peer reviewed journal: Virologica Sinica (Science Direct).
https://www.sciencedirect.com/science/article/pii/S1995820X24000361
 
For the latest about Bioweapons, China and DARPA, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/molnupiravir--what-wrong-with-america-why-is-the-american-government-and-agencies-funding-and-pushing-potentially-toxic-drugs-to-treat-covid-19
 
https://www.thailandmedical.news/news/breaking-news-china-s-foreign-ministry-official-says-that-sars-cov-2-was-brought-to-china-by-the-us-military